articles This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Article 2 months ago - 8 mins read Ten Examples of Best-in-Class Drugs It’s best to be first, but drugs that are approved later with the same mechanism of action can also create significant value for patients and society by being best-in-class (BIC), or what clinicians refer to as “gold standard.” Recently we highlighted key factors that can make a follow-on drug be considered a best-in-class drug. This… Article 3 months ago - 9 mins read The 2021 New Drug Approvals for Immunological Diseases: Deep Dive In 2021 the FDA approved four new drugs for various immunological diseases, including a molecular glue, the first drug approved for AAV in a decade, and a ROCK kinase inhibitor originally investigated for cancer. This article and slide deck explores each in more detail, including but not limited to their: mechanisms of action target rationale… Article 3 months ago - 1 min read Molecules of the Month – April 2022 Drug Hunter’s April 2022 edition of Molecules of the Month features some emerging small molecule clinical candidates as well as several interesting molecules in preclinical stages for a broad range of indications. Among these are two KRASG12C inhibitors, JDQ443 from Novartis and AZD4625 from AstraZeneca, each with unique chemical structure and binding modes, which set them… Article 3 months ago - 1 min read Highlights from Q1 2022 Webinar Part II Thank you to all of the drug hunters who attended our second drug discovery webinar! You can find the video and slides at the bottom of this page. In part II of this series we covered: Emerging startups, growing drug discovery companies, and IPOs Clinical readouts, positive and negative Big deals and major regulatory actions… Article 3 months ago - 12 mins read The 2021 New Drug Approvals for Infectious Diseases: Deep Dive The FDA in 2021 approved four novel small molecule drugs for various infectious diseases, including human immunodeficiency virus type-1 (HIV-1), post-transplant cytomegalovirus (CMV), vulvovaginal candidiasis, and human African trypanosomiasis (HAT; sleeping sickness). This article and slide deck explores each in more detail, including but not limited to their: target rationale disease context original patents key… Article 3 months ago - 7 mins read Small Molecule Long-Acting Injectables (LAIs) Leading to a Paradigm Shift in HIV Treatment and Prophylaxis In this highlight, Dr. Dennis C. Koester reviews treatment options for HIV and explains how small molecule long-acting injectables (LAIs) are offering significant promise in both HIV treatment and prophylaxis. A Coming Paradigm Shift for HIV Treatment and Prophylaxis By Dennis C. Koester The surge of the coronavirus pandemic has made our society increasingly aware… Pages: 1234567891011121314Load More
